Kinase News and Research

RSS

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration and an application for marketing authorization to the European Medicines Agency for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

1 Jul 2013

Mouse models demonstrate new potential target in fight against Alzheimer's disease

Building on research published eight years ago in the journal Chemistry and Biology, Kenneth S. Kosik, Harriman Professor in Neuroscience and co-director of the Neuroscience Research Institute (NRI) at UC Santa Barbara, and his team have now applied their findings to two distinct, well-known mouse models, demonstrating a new potential target in the fight against Alzheimer's and other neurodegenerative diseases.

27 Jun 2013

Verastem announces initiation of VS-4718 Phase 1 trial in patients with advanced cancer

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the initiation of a Phase 1 trial of VS-4718, a novel, small molecule inhibitor of focal adhesion kinase, in patients with advanced cancer.

26 Jun 2013

PLK1 crucial for proper functioning of cancer cells, researchers reveal

One of the main indicators for determining the activity of a tumour or cancer is cell division. Cancer cells divide more than other types and the genes and molecules involved in the process of division are, often, targets for identifying and treating certain types of cancer.

26 Jun 2013

Infinity announces data from IPI-145 Phase 1 study in patients with advanced hematologic malignancies

Infinity Pharmaceuticals, Inc. today announced Phase 1 data from an ongoing study of IPI-145, its potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma in patients with advanced hematologic malignancies, or potentially fatal blood cancers.

25 Jun 2013

TSRI neuroscientists fill in significant gap in the understanding of how neurons mature

Neuroscientists at The Scripps Research Institute have filled in a significant gap in the scientific understanding of how neurons mature, pointing to a better understanding of some developmental brain disorders.

21 Jun 2013

TSRI scientists find dual inhibitor that attacks two enzymes associated with Parkinson's disease

Scientists from the Florida campus of The Scripps Research Institute have found a compound that could counter Parkinson's disease in two ways at once.

21 Jun 2013

BerGenBio AS starts Phase 1 Clinical Trial for BGB324 oral AXL inhibitor

BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.

20 Jun 2013

TSRI scientists receive NIH grant to create new drug for chronic lymphocytic leukemia

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded more than $1.4 million from the National Cancer Institute of the National Institutes of Health to create a potential new drug to attack the malignant cells that cause chronic lymphocytic leukemia (CLL), which is the most common leukemia in the Western world.

20 Jun 2013

Ibrutinib shows remarkable promise for treatment of mantle cell lymphoma

In a major international study led by researchers at The University of Texas MD Anderson Cancer Center, the targeted therapy ibrutinib continues to show remarkable promise for the treatment of relapsed or refractory mantle cell lymphoma (MCL).

20 Jun 2013

Results of ibrutinib Phase 2 study in patients with mantle cell lymphoma published in NEJM

Pharmacyclics, Inc. today announced that The New England Journal of Medicine published results of a Phase 2 study evaluating the investigational oral Bruton's tyrosine kinase inhibitor ibrutinib in patients with relapsed/refractory mantle cell lymphoma online.

20 Jun 2013

Signaling pathway correlates with EGFR status and poor survival in breast cancer patients

Researchers have discovered and mapped the signaling network between two previously unconnected proteins, exposing a link that, if broken, could cut off cancer cell growth at its starting point.

19 Jun 2013

Researchers identify biochemical pathway essential for promoting head and neck cancer

A study led by researchers at The Ohio State University Comprehensive Cancer Center-- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has identified a biochemical pathway in cancer stem cells that is essential for promoting head and neck cancer.

19 Jun 2013

Moffitt Cancer Center, Advinus Therapeutics form strategic partnership

Moffitt Cancer Center announced a strategic partnership with Advinus Therapeutics to advance its discoveries to the clinics. Two promising targeted cancer therapies (Rb:Raf-1 disruptor and ROCK inhibitor) developed by Moffitt scientists are selected as the first set.

18 Jun 2013

Men with haplogroup I of Y chromosome have 50% greater risk of developing heart disease

University of Leicester scientists have discovered a potential genetic contributor to the increased risk of heart disease among men.

18 Jun 2013

Targeting SALL4 protein with druglike molecules could halt tumor growth, say researchers

Harvard Stem Cell Institute researchers have identified in the most aggressive forms of cancer a gene known to regulate embryonic stem cell self-renewal, beginning a creative search for a drug that can block its activity.

18 Jun 2013

Ibrutinib monotherapy shows efficacy in patients with MCL or DLBCL

Pharmacyclics, Inc. today announced the results of two separate Phase 2 studies suggesting that ibrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, showed efficacy when used as a monotherapy in patients with relapsed/refractory mantle cell lymphoma or diffuse large B-cell lymphoma.

17 Jun 2013

Protein expressed during embryogenesis is responsible for cancer metastasis

A protein used by embryo cells during early development, and recently found in many different types of cancer, apparently serves as a switch regulating the spread of cancer, known as metastasis, report researchers at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center in the June 15, 2013 issue of the journal Cancer Research.

14 Jun 2013

Verastem's VS-6063 gets orphan drug designation from European Commission for use in mesothelioma

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that VS-6063 has received orphan medicinal product designation from the European Commission for use in mesothelioma.

13 Jun 2013

Slowdowns in transport of important molecules may contribute to development of ALS

Slowdowns in the transport and delivery of nutrients, proteins and signaling molecules within nerve cells may contribute to the development of the neurodegenerative disorder ALS, according to researchers at the University of Illinois at Chicago College of Medicine.

13 Jun 2013

Kinase News and Research

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Mouse models demonstrate new potential target in fight against Alzheimer's disease

Verastem announces initiation of VS-4718 Phase 1 trial in patients with advanced cancer

PLK1 crucial for proper functioning of cancer cells, researchers reveal

Infinity announces data from IPI-145 Phase 1 study in patients with advanced hematologic malignancies

TSRI neuroscientists fill in significant gap in the understanding of how neurons mature

TSRI scientists find dual inhibitor that attacks two enzymes associated with Parkinson's disease

BerGenBio AS starts Phase 1 Clinical Trial for BGB324 oral AXL inhibitor

TSRI scientists receive NIH grant to create new drug for chronic lymphocytic leukemia

Ibrutinib shows remarkable promise for treatment of mantle cell lymphoma

Results of ibrutinib Phase 2 study in patients with mantle cell lymphoma published in NEJM

Signaling pathway correlates with EGFR status and poor survival in breast cancer patients

Researchers identify biochemical pathway essential for promoting head and neck cancer

Moffitt Cancer Center, Advinus Therapeutics form strategic partnership

Men with haplogroup I of Y chromosome have 50% greater risk of developing heart disease

Targeting SALL4 protein with druglike molecules could halt tumor growth, say researchers

Ibrutinib monotherapy shows efficacy in patients with MCL or DLBCL

Protein expressed during embryogenesis is responsible for cancer metastasis

Verastem's VS-6063 gets orphan drug designation from European Commission for use in mesothelioma

Slowdowns in transport of important molecules may contribute to development of ALS

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News